曲妥珠单抗德鲁德替康治疗晚期乳腺癌her2低表达:最新研究综述

Q4 Medicine

Opuholi Zenskoj Reproduktivnoj Sistemy Pub Date : 2023-10-27 DOI:10.17650/1994-4098-2023-19-3-63-76

I. V. Kolyadina

{"title":"曲妥珠单抗德鲁德替康治疗晚期乳腺癌her2低表达:最新研究综述","authors":"I. V. Kolyadina","doi":"10.17650/1994-4098-2023-19-3-63-76","DOIUrl":null,"url":null,"abstract":"The review gives the definition of HER2-low status, shows its clinical and biological role in patients with advanced breast cancer. A unique mechanism of action of trastuzumab deruxtecan and potential for its use in advanced breast cancer with HER2-low expression are described. The key results of the open multicenter phase III DESTINY-Breast04 (DB-04) trial including safety data are presented. Results on the effectiveness of the drug in patients with markers of hormone resistance first presented in 2023 and the place of trastuzumab deruxtecan in the updated ESMO 2023 algorithm of hormone-positive breast cancer treatment are considered.","PeriodicalId":36091,"journal":{"name":"Opuholi Zenskoj Reproduktivnoj Sistemy","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Trastuzumab deruxtecan in the treatment of patients with advanced breast cancer with HER2-low expression: Recent studies review\",\"authors\":\"I. V. Kolyadina\",\"doi\":\"10.17650/1994-4098-2023-19-3-63-76\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The review gives the definition of HER2-low status, shows its clinical and biological role in patients with advanced breast cancer. A unique mechanism of action of trastuzumab deruxtecan and potential for its use in advanced breast cancer with HER2-low expression are described. The key results of the open multicenter phase III DESTINY-Breast04 (DB-04) trial including safety data are presented. Results on the effectiveness of the drug in patients with markers of hormone resistance first presented in 2023 and the place of trastuzumab deruxtecan in the updated ESMO 2023 algorithm of hormone-positive breast cancer treatment are considered.\",\"PeriodicalId\":36091,\"journal\":{\"name\":\"Opuholi Zenskoj Reproduktivnoj Sistemy\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-10-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Opuholi Zenskoj Reproduktivnoj Sistemy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.17650/1994-4098-2023-19-3-63-76\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Opuholi Zenskoj Reproduktivnoj Sistemy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17650/1994-4098-2023-19-3-63-76","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

本文给出了her2低状态的定义，并阐述了其在晚期乳腺癌患者中的临床和生物学作用。本文描述了曲妥珠单抗德鲁德替康的独特作用机制及其在her2低表达晚期乳腺癌中的应用潜力。公开多中心III期DESTINY-Breast04 (DB-04)试验的关键结果，包括安全性数据。考虑该药在2023年首次出现激素耐药标记的患者中的有效性，以及曲妥珠单抗德鲁德替康在更新后的ESMO 2023激素阳性乳腺癌治疗算法中的位置。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Trastuzumab deruxtecan in the treatment of patients with advanced breast cancer with HER2-low expression: Recent studies review

The review gives the definition of HER2-low status, shows its clinical and biological role in patients with advanced breast cancer. A unique mechanism of action of trastuzumab deruxtecan and potential for its use in advanced breast cancer with HER2-low expression are described. The key results of the open multicenter phase III DESTINY-Breast04 (DB-04) trial including safety data are presented. Results on the effectiveness of the drug in patients with markers of hormone resistance first presented in 2023 and the place of trastuzumab deruxtecan in the updated ESMO 2023 algorithm of hormone-positive breast cancer treatment are considered.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Opuholi Zenskoj Reproduktivnoj Sistemy Medicine-Obstetrics and Gynecology

CiteScore

0.50

自引率

0.00%

发文量

审稿时长

10 weeks